# Maria Shipkova

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 102 papers | 4,827 citations | 87723 38 h-index | 98622 67 g-index |
| 102 all docs | 102 docs citations | 102 times ranked | 3702 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307. | 1.0 | 374 |
| 2 | Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications. Therapeutic Drug Monitoring, 2003, 25, 1-16. | 1.0 | 250 |
| 3 | The Pharmacokinetic-Pharmacodynamic Relationship for Total and Free Mycophenolic Acid in Pediatric Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2002, 13, 759-768. | 3.0 | 225 |
| 4 | Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. British Journal of Pharmacology, 1999, 126, 1075-1082. | 2.7 | 189 |
| 5 | Pharmacokinetic and Metabolic Investigations of Mycophenolic Acid in Pediatric Patients After Renal Transplantation: Implications for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2000, 22, 20-26. | 1.0 | 171 |
| 6 | Surface markers of lymphocyte activation and markers of cell proliferation. Clinica Chimica Acta, 2012, 413, 1338-1349. | 0.5 | 153 |
| 7 | Determination of the Acyl Glucuronide Metabolite of Mycophenolic Acid in Human Plasma by HPLC and Emit. Clinical Chemistry, 2000, 46, 365-372. | 1.5 | 149 |
| 8 | Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation, 2003, 75, 665-672. | 0.5 | 142 |
| 9 | Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?. Clinical Biochemistry, 2000, 33, 107-113. | 0.8 | 141 |
| 10 | Identification of a Pharmacologically Active Metabolite of Mycophenolic Acid in Plasma of Transplant Recipients Treated with Mycophenolate Mofetil. Clinical Chemistry, 1999, 45, 419-422. | 1.5 | 140 |
| 11 | Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clinical Chemistry, 1998, 44, 1481-1488. | 1.5 | 121 |
| 12 | Comparison of the Emit Immunoassay with HPLC for Therapeutic Drug Monitoring of Mycophenolic Acid in Pediatric Renal-Transplant Recipients on Mycophenolate Mofetil Therapy. Clinical Chemistry, 2002, 48, 517-525. | 1.5 | 112 |
| 13 | Area Under the Plasma Concentrationâ€“Time Curve for Total, But Not for Free, Mycophenolic Acid Increases in the Stable Phase After Renal Transplantation: A Longitudinal Study in Pediatric Patients. Therapeutic Drug Monitoring, 1999, 21, 498. | 1.0 | 105 |
| 14 | 6-Thioguanine Nucleotideâ€“Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial. Clinical Chemistry, 2007, 53, 1306-1314. | 1.5 | 104 |
| 15 | Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169. | 1.0 | 102 |
| 16 | Differences in Nucleotide Hydrolysis Contribute to the Differences between Erythrocyte 6-Thioguanine Nucleotide Concentrations Determined by Two Widely Used Methods. Clinical Chemistry, 2003, 49, 260-268. | 1.5 | 98 |
| 17 | Measurement of Erythrocyte Inosine Triphosphate Pyrophosphohydrolase (ITPA) Activity by HPLC and Correlation of ITPA Genotype-Phenotype in a Caucasian Population. Clinical Chemistry, 2006, 52, 240-247. | 1.5 | 97 |
| 18 | Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. Therapeutic Drug Monitoring, 2016, 38, 170-189. | 1.0 | 95 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients. Therapeutic Drug Monitoring, 2002, 24, 390-399. | 1.0 | 93 |
| 20 | Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200. | 1.0 | 89 |
| 21 | Association of Inosine Triphosphatase 94C>A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study. Clinical Chemistry, 2005, 51, 2282-2288. | 1.5 | 88 |
| 22 | Validation of a Rapid and Sensitive Liquid Chromatographyâ€“Tandem Mass Spectrometry Method for Free and Total Mycophenolic Acid. Clinical Chemistry, 2004, 50, 152-159. | 1.5 | 84 |
| 23 | Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2016, 38, S1-S20. | 1.0 | 78 |
| 24 | Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 505-526. | 1.5 | 77 |
| 25 | Effect of Cyclosporine Withdrawal on Mycophenolic Acid Pharmacokinetics in Kidney Transplant Recipients With Deteriorating Renal Function: Preliminary Report. Therapeutic Drug Monitoring, 2001, 23, 717-721. | 1.0 | 70 |
| 26 | LCâ€“MS/MS as a tool for TDM services: Where are we?. Clinical Biochemistry, 2016, 49, 1009-1023. | 0.8 | 65 |
| 27 | Bioavailability of Mycophenolate Mofetil and Entericâ€Coated Mycophenolate Sodium Is Differentially Affected by Pantoprazole in Healthy Volunteers. Journal of Clinical Pharmacology, 2009, 49, 1196-1201. | 1.0 | 59 |
| 28 | Analytic Aspects of Monitoring Therapy with Thiopurine Medications. Therapeutic Drug Monitoring, 2004, 26, 220-226. | 1.0 | 54 |
| 29 | Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. Therapeutic Drug Monitoring, 2010, 32, 560-572. | 1.0 | 54 |
| 30 | Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. Clinical Biochemistry, 2004, 37, 204-209. | 0.8 | 50 |
| 31 | Glucuronidation in therapeutic drug monitoring. Clinica Chimica Acta, 2005, 358, 2-23. | 0.5 | 47 |
| 32 | Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics, 2004, 4, 2728-2738. | 1.3 | 46 |
| 33 | Phenotypic and Genotypic Analysis of Thiopurine S-Methyltransferase Polymorphism in the Bulgarian Population. Therapeutic Drug Monitoring, 2003, 25, 631-636. | 1.0 | 44 |
| 34 | Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie, 2007, 89, 393-402. | 1.3 | 44 |
| 35 | Analysis of ITPA Phenotype-Genotype Correlation in the Bulgarian Population Revealed a Novel Gene Variant in Exon 6. Therapeutic Drug Monitoring, 2007, 29, 6-10. | 1.0 | 40 |
| 36 | Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 503-511. | 2.2 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Association Between Adverse Effects Under Azathioprine Therapy and Inosine Triphosphate Pyrophosphatase Activity in Patients With Chronic Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2011, 33, 321-328. | 1.0 | 40 |
| 38 | Lymphocyte surface molecules as immune activation biomarkers. Clinical Biochemistry, 2016, 49, 347-354. | 0.8 | 39 |
| 39 | A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrology Dialysis Transplantation, 2002, 17, 923-926. | 0.4 | 38 |
| 40 | Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant Recipients. Therapeutic Drug Monitoring, 2005, 27, 315-321. | 1.0 | 34 |
| 41 | Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. Clinical Biochemistry, 2014, 47, 1069-1077. | 0.8 | 32 |
| 42 | Improved Method for Therapeutic Drug Monitoring of 6-Thioguanine Nucleotides and 6-Methylmercaptopurine in Whole-Blood by LC/MSMS Using Isotope-Labeled Internal Standards. Therapeutic Drug Monitoring, 2013, 35, 313-321. | 1.0 | 31 |
| 43 | Determination of Thiopurine Methyltransferase Phenotype in Isolated Human Erythrocytes Using a New Simple Nonradioactive HPLC Method. Therapeutic Drug Monitoring, 2003, 25, 637-644. | 1.0 | 30 |
| 44 | The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. Journal of Heart and Lung Transplantation, 2011, 30, 565-571. | 0.3 | 30 |
| 45 | Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. Therapeutic Drug Monitoring, 2019, 41, 180-191. | 1.0 | 30 |
| 46 | Comparability and Imprecision of 8 Frequently Used Commercially Available Immunoassays for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2014, 36, 433-441. | 1.0 | 29 |
| 47 | Cyclosporin A Absorption Profiles in Pediatric Renal Transplant Recipients Predict the Risk of Acute Rejection. Therapeutic Drug Monitoring, 2004, 26, 415-424. | 1.0 | 28 |
| 48 | Investigation of the Crossreactivity of Mycophenolic Acid Glucuronide Metabolites and of Mycophenolate Mofetil in the Cedia MPA Assay. Therapeutic Drug Monitoring, 2010, 32, 79-85. | 1.0 | 27 |
| 49 | Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clinical Biochemistry, 2000, 33, 203-208. | 0.8 | 26 |
| 50 | Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients. Transplantation, 2011, 91, 779-785. | 0.5 | 26 |
| 51 | SYNERGISTIC EFFECTS OF SIROLIMUS WITH CYCLOSPORINE AND TACROLIMUS: ANALYSIS OF IMMUNOSUPPRESSION ON LYMPHOCYTE PROLIFERATION AND ACTIVATION IN RAT WHOLE BLOOD. Transplantation, 2004, 77, 1154-1162. | 0.5 | 25 |
| 52 | Multicenter Analytical Evaluation of the Automated Electrochemiluminescence Immunoassay for Cyclosporine. Therapeutic Drug Monitoring, 2014, 36, 640-650. | 1.0 | 23 |
| 53 | Liquid chromatography tandem mass spectrometry for therapeutic drug monitoring of immunosuppressive drugs: Achievements, lessons and open issues. TrAC - Trends in Analytical Chemistry, 2016, 84, 23-33. | 5.8 | 22 |
| 54 | Quantification of Mycophenolic Acid in Plasma Samples Collected during and Immediately after Intravenous Administration of Mycophenolate Mofetil. Clinical Chemistry, 2001, 47, 1485-1488. | 1.5 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Irinotecan in Cancer Patients with End-Stage Renal Failure. Annals of Pharmacotherapy, 2009, 43, 363-369. | 0.9 | 20 |
| 56 | Stability of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Human Plasma. Clinical Chemistry, 1999, 45, 127-129. | 1.5 | 19 |
| 57 | Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. Transplantation Reviews, 2017, 31, 151-157. | 1.2 | 19 |
| 58 | Improving Therapeutic Decisions: Pharmacodynamic Monitoring as an Integral Part of Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2019, 41, 111-114. | 1.0 | 19 |
| 59 | Determination of Thiopurine Methyltransferase Activity in Isolated Human Erythrocytes Does Not Reflect Putative in Vivo Enzyme Inhibition by Sulfasalazine. Clinical Chemistry, 2004, 50, 438-441. | 1.5 | 18 |
| 60 | cDNA Microarray Analysis Reveals New Candidate Genes Possibly Linked to Side Effects Under Mycophenolate Mofetil Therapy. Transplantation, 2004, 78, 1145-1152. | 0.5 | 18 |
| 61 | Mycophenolic Acid Interaction With Cyclosporine and Tacrolimus In Vitro and In Vivo. Therapeutic Drug Monitoring, 2005, 27, 123-131. | 1.0 | 18 |
| 62 | Editorial: Immune monitoring in solid organ transplantation. Clinical Biochemistry, 2016, 49, 317-319. | 0.8 | 18 |
| 63 | Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood. Clinical Chemistry and Laboratory Medicine, 2016, 54, 437-46. | 1.4 | 18 |
| 64 | Association Between Pharmacodynamic Biomarkers and Clinical Events in the Early Phase After Kidney Transplantation: A Single-Center Pilot Study. Therapeutic Drug Monitoring, 2011, 33, 341-349. | 1.0 | 17 |
| 65 | The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center. Frontiers in Genetics, 2019, 10, 871. | 1.1 | 17 |
| 66 | Pharmacokinetics and pharmacodynamics of mycophenolate sodium (ECâ€MPS) coâ€administered with cyclosporine in the earlyâ€phase postâ€kidney transplantation. Clinical Transplantation, 2012, 26, 57-66. | 0.8 | 14 |
| 67 | Increased Cyclosporine Concentrations in the Absence of Cyclosporine Administration. Clinical Chemistry, 2011, 57, 670-673. | 1.5 | 13 |
| 68 | Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients. Transplantation, 2017, 101, 2780-2788. | 0.5 | 13 |
| 69 | Differential Proteomic Analysis of Lymphocytes Treated With Mycophenolic Acid Reveals Caspase 3-Induced Cleavage of Rho GDP Dissociation Inhibitor 2. Therapeutic Drug Monitoring, 2009, 31, 211-217. | 1.0 | 12 |
| 70 | Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method. Therapeutic Drug Monitoring, 2017, 39, 102-108. | 1.0 | 12 |
| 71 | Evaluation of an Immunoassay for Mycophenolic Acid. Therapeutic Drug Monitoring, 2000, 22, 141. | 1.0 | 11 |
| 72 | The Monoethylglycinexylidide (MEGX) Test as a Marker of Hepatic Dysfunction in Septic Patients with Pneumonia. Clinical Chemistry and Laboratory Medicine, 2000, 38, 1125-8. | 1.4 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | MYCOPHENOLATE MOFETIL DECREASES ENDOTHELIAL PROSTAGLANDIN E 2 IN RESPONSE TO ALLOGENEIC T CELLS OR CYTOKINES1. Transplantation, 2000, 69, 1977-1981. | 0.5 | 10 |
| 74 | Determination of monoethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: modified precipitation procedure and HPLC compared. Clinical Chemistry, 1998, 44, 1269-1274. | 1.5 | 8 |
| 75 | Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors. Therapeutic Drug Monitoring, 2016, 38, 711-716. | 1.0 | 8 |
| 76 | Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation. Clinical Chemistry and Laboratory Medicine, 2018, 56, 764-775. | 1.4 | 8 |
| 77 | Atypical Pharmacokinetics and Metabolism of Mycophenolic Acid in a Young Kidney Transplant Recipient With Impaired Renal Function. Therapeutic Drug Monitoring, 2002, 24, 438-443. | 1.0 | 7 |
| 78 | CD26/dipeptidyl peptidase IV: A comparative study of healthy persons and kidney transplant recipients before and early after transplantation. Clinical Biochemistry, 2013, 46, 1383-1388. | 0.8 | 7 |
| 79 | Multicenter Evaluation of a New Electrochemiluminescence Immunoassay for Everolimus Concentrations in Whole Blood. Therapeutic Drug Monitoring, 2018, 40, 59-68. | 1.0 | 7 |
| 80 | A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. Clinical Nephrology, 2013, 79, 421-431. | 0.4 | 7 |
| 81 | The acyl glucuronide metabolite of mycophenolic acid induces tubulin polymerization in vitro. Clinical Biochemistry, 2010, 43, 208-213. | 0.8 | 6 |
| 82 | Biomarkers in transplantation medicine: Guide to the next level in immunosuppressive therapy. Clinica Chimica Acta, 2012, 413, 1309. | 0.5 | 6 |
| 83 | Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. Therapeutic Drug Monitoring, 2016, 38, S80-S92. | 1.0 | 6 |
| 84 | Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. Therapeutic Drug Monitoring, 2022, 44, 32-49. | 1.0 | 6 |
| 85 | Rapid and Sensitive Liquid Chromatographyâ€“Tandem Mass Spectrometry Method for Determination of Monoethylglycinexylidide. Clinical Chemistry, 2001, 47, 1853-1856. | 1.5 | 5 |
| 86 | Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition. Clinical Biochemistry, 2016, 49, 1181-1187. | 0.8 | 5 |
| 87 | Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 612-619. | 0.6 | 5 |
| 88 | Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humans. Hepatology, 1998, 28, 1439-1440. | 3.6 | 4 |
| 89 | Regulation of IL2 and NUCB1 in Mononuclear Cells Treated With Acyl Glucuronide of Mycophenolic Acid Reveals Effects Independent of Inosine Monophosphate Dehydrogenase Inhibition. Therapeutic Drug Monitoring, 2009, 31, 31-41. | 1.0 | 3 |
| 90 | Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate. Clinical Chemistry and Laboratory Medicine, 2018, 56, 803-809. | 1.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liver perfusion model. Clinical Biochemistry, 2001, 34, 53-57. | 0.8 | 2 |
| 92 | A Simple And Rapid High-performance Liquid Chromatographic Procedure for Determination Of Inosine 5??-monophosphate Dehydrogenase Activity in Isolated Human Mononuclear Blood Cells (Mbc). Therapeutic Drug Monitoring, 2005, 27, 253. | 1.0 | 2 |
| 93 | Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von MycophenolsÃure in der Transplantationsmedizin: Wo stehen wir?. Laboratoriums Medizin, 2009, 33, 88-98. | 0.1 | 1 |
| 94 | Biomarkers. , 2012, , 349-372. | | 1 |
| 95 | Analytical evaluation of a real-time PCR-based DNA demethylation assay to assess the frequency of naturally occurring regulatory T cells in peripheral blood. Clinical Biochemistry, 2016, 49, 1173-1180. | 0.8 | 1 |
| 96 | T-Cell Surface Antigens and sCD30 as Biomarkers of the Risk of Rejection in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2016, 38, S29-S35. | 1.0 | 1 |
| 97 | Biomarker monitoring in immunosuppressant therapy. , 2016, , 125-152. | | 1 |
| 98 | Therapie mit Thiopurin-Medikamenten - TDM und Pharmakogenomik der TPMT. Therapy with Thiopurine Drugs - TDM and Pharmacogenomics of TPMT. Laboratoriums Medizin, 2003, 27, 211-221. | 0.1 | 0 |
| 99 | Therapie mit Thiopurin-Medikamenten TDM â€“ und Pharmakogenomik der TPMT/Therapy with Thiopurine Drugs â€“ TDM and Pharmacogenomics of TPMT. Laboratoriums Medizin, 2003, 27, 211-221. | 0.1 | 0 |
| 100 | Analytic Aspects of Monitoring Therapy with Thiopurine Medications. ChemInform, 2005, 36, no. | 0.1 | 0 |
| 101 | Biomarker im Blut zur Individualisierung der immunsuppressiven Therapie nach der Transplantation solider Organe. Laboratoriums Medizin, 2014, 38, 333-343. | 0.1 | 0 |
| 102 | Biomarkers in blood for individualization of the pharmacotherapy with immunosuppressive drugs after transplantation of solid organs. Laboratoriums Medizin, 2015, 38, . | 0.1 | 0 |